HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults

Journal of Nutritional Biochemistry

Volumn 18, Issue 9, 2007, Pages 629-634

  Zenk, John L ^a   Frestedt, Joy L ^a   Kuskowski, Michael A ^b  

^a Minnesota Applied Research Center   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

3 acetyl 7 oxo dehydroepiandrosterone; Clinical trial; Obesity; Resting metabolic rate; Weight loss

Indexed keywords

3 ACETYL 7 OXO DEHYDROEPIANDROSTERONE; 7 KETO; ANTIOBESITY AGENT; ASCORBIC ACID; CHROMIUM DERIVATIVE; CHROMIUM NICOTINATE; CITRATE CALCIUM; COLECALCIFEROL; GREEN TEA EXTRACT; HUM 5007; PLACEBO; THERMOGENIC COMPOUND; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CALORIC RESTRICTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; ENERGY EXPENDITURE; FEMALE; FLATULENCE; HEART PALPITATION; HUMAN; KNEE INJURY; MALE; METABOLIC RATE; MONOTHERAPY; NAUSEA; OBESITY; RANDOMIZED CONTROLLED TRIAL; SHOULDER INJURY; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; WEIGHT REDUCTION;

ADULT; ASCORBIC ACID; BASAL METABOLISM; CALORIC RESTRICTION; CAMELLIA SINENSIS; CHOLECALCIFEROL; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC ACIDS; ORGANOMETALLIC COMPOUNDS; OVERWEIGHT; PLANT EXTRACTS;

EID: 34547690937     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2006.11.008     Document Type: Article

References (57)

1. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
2. Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., and Koplan J.P. The continuing epidemics of obesity and diabetes in the United States. JAMA 286 (2001) 1195-1200
3. Calle E.E., Thum M.J., Petrelli J.M., Rodriguez C., and Heath C.W. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 341 (1999) 1097-1105
4. Markus R.A., Mack W.J., Azen S.P., and Hodis H.N. Influence of lifestyle modification on atherosclerotic progression determined by ultrasonographic change in the common carotid intimal-media thickness. Am J Clin Nutr 65 (1997) 1000-1004
5. Nisoli E., and Carruba M.O. Emerging aspects of pharmacotherapy for obesity and metabolic syndrome. Pharmacol Res 50 (2004) 453-469
6. Colditz G.A. Economic costs of obesity. Am J Clin Nutr 55 (1992) 503S-507S
7. Mokdad A.H., Marks J.S., Stroup D.F., and Gerberdine J.L. Actual causes of death in the United States, 2000. JAMA 291 (2004) 1238-1245
8. Astrup A. Thermogenic drugs as a strategy for treatment of obesity. Endocrine 13 (2000) 207-212
9. Astrup A. Macronutrient balances and obesity: the role of diet and physical activity. Public Health Nutr 2 (1999) 341-347
10. Ravussin E., and Swinburn B.A. Metabolic predictors of obesity: cross-sectional versus longitudinal data. Int J Obes Relat Metab Disord 17 Suppl 3 (1993) S28-S31
11. Cunningham J.J. Body composition as a determinant of energy expenditure: a synthetic review and a proposed general prediction equation. Am J Clin Nutr 54 (1991) 963-969
12. Leibel R.L., Rosenbaum M., and Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 332 (1995) 621-628
13. Bray G.A. The MONA LISA hypothesis. Most obesities known are low in sympathetic activity. In: Oomura Y., Tarui S., Inoue S., and Shimazu T. (Eds). Progress in obesity research (1990), John Libbey & Co, London 61-66
14. Lardy H., Partridge B., Kneer N., and Wei Y. Ergosteroids: induction of thermogenic enzymes in liver of rats treated with steroids derived from dehydroepiandrosterone. Proc Natl Acad Sci U S A 92 (1995) 6617-6619
15. Bobyleva V., Bellei M., Kneer N., and Lardy H. The effects of the ergosteroid 7-oxo-dehydroepiandrosterone on mitochondrial membrane potential: possible relationship to thermogenesis. Arch Biochem Biophys 341 (1997) 122-128
16. Miyamoto H., Yeh S., Lardy H., Messing E., and Chang C. Delta-5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci U S A 95 (1998) 11083-11088
17. Davidson M., Marwah A., Sawchuk R.J., Maki K., Marwah P., Weeks C., et al. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. Clin Invest Med 23 (2000) 300-310
18. Lardy H., Kneer N., Wei Y., Partridge B., and Marwah P. Ergosteroids II: biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. Steroids 63 (1998) 158-165
19. Kalman D.S., Colker C.M., Swain M.A., Torina G.C., and Shi Q. A randomized, double blind, placebo controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy overweight adults. Curr Ther Res 61 (2000) 35-442
20. Zenk J.L., Helmer T.R., Kassen L.J., and Kuskowski M.A. The effect of 7-Keto Naturalean on weight loss: a randomized, double-blind, placebo-controlled trial. Curr Ther Res 63 (2002) 263-272
21. Landsberg L., and Young J.B. Sympathoadrenal activity and obesity: physiological rationale for the use of adrenergic thermogenic drugs. Int J Obes Relat Metab Disord 17 (1993) S29-S34
22. Dulloo A.G., Duret C., Rohrer D., Girardier L., Mensi N., Fathi M., et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 70 (1999) 1040-1045
23. Tian W.X., Li L.C., Wu X.D., and Chen C.C. Weight reduction by Chinese medicinal herbs may be related to inhibition of fatty acid synthase. Life Sci 74 (2004) 2389-2399
24. Anderson R.A. Effects of chromium on body composition and weight loss. Nutr Rev 56 (1998) 266-270
25. Preus H.G., and Anderson R.A. Chromium update: examining recent literature 1997-1998. Curr Opin Clin Nutr Metab Care 1 (1998) 509-512
26. Anderson R.A., Polansky M.M., and Bryden M.A. Stability and absorption of chromium and absorption of chromium histidinate complexes by humans. Biol Trace Elem Res 101 (2004) 211-218
27. Hoeger W.W., Harris C., Long E.M., and Hopkins D.R. Four-week supplementation with a natural dietary compound produces favorable changes in body composition. Adv Ther 15 (1998) 305-314
28. Bahadori B., Wallner S., Schneider H., Wascher T.C., and Toplak H. Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic subjects during and after a formula diet. Acta Med Austriaca 24 (1997) 185-187
29. Kaats G.R., Blum K., Fisher J.A., and Adelman J.A. Effects of chromium picolinate supplementation on body composition: A randomized, double masked, placebo controlled study. Curr Ther Res 57 (1996) 747-756
30. Kaats G.R., Blum K., Pullin D., Keith S.C., and Wood R. A randomized, double masked, placebo controlled study of the effects of chromium picolinate supplementation on body composition: a replication and extension of a previous study. Curr Ther Res 59 (1998) 379-388
31. Crawford V., Scheckenbach R., and Preuss H.G. Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. Diabetes Obes Metab 1 (1999) 331-337
32. Offenbacher E.G. Promotion of chromium absorption by ascorbic acid. J Trace Elem Electrolytes Health Dis 11 (1994) 178-181
33. Zemel M.B. Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. J Am Coll Nutr 21 (2002) 146S-151S
34. Zemel M.B., Shi H., Greer B., DiRienzo D., and Zemel P.C. Regulation of adiposity by dietary calcium. FASEB J 14 (2000) 1132-1138
35. Shi H., DiRienzo D., and Zemel M.B. Effects of dietary calcium on adipocyte lipid metabolism and body weight regulation in energy-restricted aP2-agouti transgenic mice. FASEB J 15 (2001) 291-293
36. Heaney R.P., Davies M., and Barger-Lux M.J. Calcium and weight: clinical studies. J Am Coll Nutr 21 (2002) 152S-155S
37. Teegarden D. Calcium intake and reduction in weight or fat mass. J Nutr 133 (2003) 249S-251S
38. Davies K.M., Heaney R.P., Recker R.R., Lappe J.M., Barger-Lux M.J., Rafferty K., et al. Calcium intake and body weight. J Clin Endocrinol Metab 85 (2000) 4635-4638
39. Lin Y.C., Lyle R.M., McCabe L.D., McCabe G.P., Weaver C.M., and Teegarden D. Dairy calcium is related to changes in body composition during a two-year exercise intervention in young women. J Am Coll Nutr 19 (2000) 754-760
40. Zemel M.B., Thompson W., Milstead A., Morris K., and Campbell P. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. Obes Res 12 (2004) 582-590
41. Zemel M.B., Richards J., Mathis S., Milstead A., Gebhardt L., and Silva E. Dairy augmentation of total and central fat loss in obese subjects. Int J Obes Relat Metab Disord 29 (2005) 391-397
42. Marcus R. Agents affecting calcification and bone turnover - calcium, phosphate, parathyroid hormone, vitamin D, calcitonin, and other compounds. In: Hardman J.G., Limbird L.E., Molinoff P.B., and Ruddon R.W. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics (1996), McGraw Hill, New York 1529-1536
43. Anonymous. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285 (2001) 785-795
44. Mortensen L., and Charles P. Bioavailability of calcium supplements and the effect of vitamin D: comparisons between milk, calcium citrate, and calcium citrate plus vitamin D. Am J Clin Nutr 63 (1996) 354-357
45. Bronner F. Mechanisms and functional aspects of intestinal calcium absorption. J Exp Zoolog A Comp Exp Biol 300 (2003) 47-52
46. Bouillon R., Van Cromphaut S., and Carmeliet G. Intestinal calcium absorption: molecular vitamin D mediated mechanisms. J Cell Biochem 88 (2003) 332-339
47. Hoenderop J.G., Nilius B., and Bindels R.J. Calcium absorption across the epithelium. Physiol Rev 85 (2005) 373-422
48. Danforth E. Diet and obesity. Am J Clin Nutr 41 (1985) 1132-1145
49. Schutz Y., and Jequier E. Energy metabolism and dietary-induced thermogenesis in lean and obese subjects. In: Lardy H., and Stratman F. (Eds). Hormones, thermogenesis and obesity (1989), Elsevier Science Publishing Co. Inc, New York 59-64
50. Bouchard C., Tremblay A., and Nadeau A. Genetic effect in resting and exercise metabolic rates. Metab Clin Exp 38 (1989) 364-370
51. Astrup A.V., Simonsen L., Bulow J., and Christensen N.J. The contribution of skeletal muscle to carbohydrate-induced thermogenesis in man. The role of the sympathoadrenal system. In: Lardy H., and Stratman F. (Eds). Hormones, Thermogenesis and obesity (1989), Elsevier Science Publishing Co. Inc, New York 187-196
52. Ravussin E., Lillioja S., and Knowler W.C. Reduced rate of energy expenditure as a risk factor for body-weight gain. N Eng J Med 318 (1988) 467-472
53. Ravussin E., Burnand B., Schutz Y., and Jequier E. Energy expenditure before and during energy restriction in obese subjects. Am J Clin Nutr 41 (1985) 753-759
54. Leibel R.L., and Hirsch J. Diminished energy requirements in reduced-obese subjects. Metab Clin Exp 33 (1984) 164-170
55. Shutz Y., Golay A., Felber J.P., and Jequier E. Decreased glucose-induced thermogenesis after weight loss in obese subjects: a predisposing factor for relapse of obesity?. Am J Clin Nutr 39 (1984) 380-387
56. Lennon D., Nagle F., Stratman F., Shrago E., and Dennis S. Diet and exercise training effects on resting metabolic rates. Int J Obes 9 1 (1985) 39-47
57. Astrup A., Gotzsche P.C., van de Werken K., Ranneries C., Toubro S., Raben A., et al. Meta-analysis of resting metabolic rate in formerly obese subjects. Am J Clin Nutr 69 6 (1999) 1117-1122